

bringing **Ca<sup>20</sup>** to life<sup>®</sup>  
calcium

# Pioneering calcium compound devices to carry antibiotics in bone and soft tissue

Calcium is a vital and exciting mineral. Its applications and its use in the body are widespread.

At Biocomposites, we are distinct in that our team of specialists is singularly focused on the development of innovative calcium compounds for surgical use.

Possessing unique characteristics for carrying antibiotics, regenerating bone and repairing soft tissue, our products are opening new possibilities for surgeons around the world.

At Biocomposites  
we are proud to be driving improved  
outcomes across a wide range of clinical  
applications for surgeons around the world

# bringing to life<sup>®</sup>

- Innovative approaches to infection management in bone and soft tissue
- Singular focus on calcium compound technologies
- Deep expertise
- Dedicated to quality
- Over 30 years' experience
- Products used in over 100,000 procedures per annum
- Based in Keele, UK - with companies in the USA and China and a presence in Canada, Europe and India

# Innovation is at the very heart of what we do


At Biocomposites we are proud of our series of world firsts. For us, innovation is an ongoing process. Our continuing investment in proprietary technologies has resulted in over 100 IP grants and registrations and positioned us at the frontier of musculoskeletal infection, trauma, spine and sports injuries.



## STIMULAN<sup>®</sup>

FIRST calcium sulfate antibiotic carrier to receive CE mark for use in bone and soft tissue.

FIRST recrystallised calcium sulfate to receive clearance from the FDA.



## genex<sup>®</sup>

FIRST synthetic bone-graft material with negatively charged surface chemistry to accelerate bone healing.



## Bilok<sup>®</sup>

FIRST calcium composite device in sports injuries to receive both the CE mark and clearance from the FDA.

## DEDICATED TO QUALITY

*Exacting and consistent specifications to ensure reliable, predictable and reproducible clinical performance.*

Our products are tried and trusted around the world to change lives. We believe that much of our success in over 40 countries worldwide is due to the confidence our surgeons have in our quality control.

At our state-of-the-art facility in Keele, UK, we operate to the highest international standards. Every stage of the process, from research, through manufacture to distribution, is all handled in-house.

*By having 100% ownership of the production process at a single site, we create an unrivalled level of confidence in our products.*



Our innovative calcium compound devices range from bone grafts to antibiotic carriers for use in bone and soft tissue. Possessing unique characteristics for regenerating bone and managing infected sites, our products are opening new possibilities for surgeons around the world.

## STIMULAN<sup>®</sup>

Truly absorbable calcium sulfate antibiotic carrier approved for use in bone and soft tissue

## genex<sup>®</sup>

An innovative, versatile synthetic bone graft that supports natural healing and vanishes without a trace

## Allogran R<sup>®</sup>

Highly consistent, polycrystalline and porous calcium phosphate bone substitute for use in trauma and spine.

## Biosteon<sup>®</sup>

Osteoconductive calcium phosphate composite with improved strength retention and bone-bonding potential.

## Bilok<sup>®</sup>

First synthetic calcium composite arthroscopic device in sport injuries to receive CE mark and FDA clearance.

Find out more at [biocomposites.com](http://biocomposites.com)

©2020, Biocomposites, STIMULAN, genex, Biosteon, Bringing Calcium to Life, Power to Transform Outcomes, DRy26 and Power to Restore are trademarks/registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

Patents granted: EP I390086 BI, US 8632796, CN ZL02809194.9, US 8496955, GB2367552, EP I204599 BI, US 6780391, EP I436019 BI, US 8563024, CN ZL02825134.2, EP 2594231 BI, US 88883063, CN ZL201210466117.X, GB2496710, EP 3058899 BI, US 10390954

Patents pending: GBI502655.2, US 15/040075, CN 201610089710.5, GBI704688.9, EP I8275044 8, US 15/933936, CN 108619579A

MA0080R4